Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
Hao-Xiang WuYan-Xing ChenZi-Xian WangQi ZhaoMing-Ming HeYing-Nan WangFeng WangRui-Hua XuPublished in: Journal for immunotherapy of cancer (2019)
TET1-MUT was strongly associated with higher ORR, better DCB, longer PFS, and improved OS in patients receiving ICI treatment, suggesting that TET1-MUT is a novel predictive biomarker for immune checkpoint blockade across multiple cancer types.
Keyphrases